Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era

Dafna D. Gladman, Olga Ziouzina, Arane Thavaneswaran and Vinod Chandran
The Journal of Rheumatology August 2013, 40 (8) 1357-1359; DOI: https://doi.org/10.3899/jrheum.130163
Dafna D. Gladman
From the University of Toronto; Toronto Western Research Institute; Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases; University Health Network; Toronto Western Hospital, Toronto, Ontario; and University of Calgary, Division of Rheumatology, Department of Medicine, Calgary, Alberta, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dafna.gladman@utoronto.ca
Olga Ziouzina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arane Thavaneswaran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vinod Chandran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To determine the prevalence of acute dactylitis in patients with psoriatic arthritis (PsA) and to compare the response of new acute dactylitis to treatment with traditional disease-modifying antirheumatic drug (DMARD) and anti-tumor necrosis factor-α (anti-TNF) agents in a longitudinal PsA cohort.

Methods. Patients with PsA followed at 6 months according to a standard protocol from January 2000 to January 2010 were included in our study. Acute dactylitis was defined as the presence of painful swelling of an entire digit. Response was defined as either complete resolution of dactylitis or > 50% improvement in the number of dactylitic digits. A multivariate generalized estimating equations analysis using a negative binomial model to account for repeated measures was conducted to determine predictors for response to treatment of dactylitis.

Results. Of the 752 patients seen in the clinic during this period, 294 had dactylitis in at least 1 visit, giving a prevalence of 39%. Patients with acute dactylitis and data available for response at 6 and 12 months (n = 252; 34% women, mean age 47 yrs, PsA duration 11 yrs) were included in the study on predictors of response to treatment. Multivariate analysis showed that treatment with anti-TNF agents was a significant predictor of improvement in dactylitis at 12 months (relative risk 0.528, 95% CI 0.283–0.985, p = 0.045).

Conclusion. The prevalence of dactylitis on at least 1 visit was 39%. Treatment was associated with improvement of dactylitis. Patients treated with biologics had better response to treatment compared with those treated with nonbiologic DMARD alone.

Key Indexing Terms:
  • SPONDYLOARTHRITIS
  • DISEASE-MODIFYING ANTIRHEUMATIC DRUG
  • INFLAMMATION
  • BIOLOGICS
  • DACTYLITIS

Dactylitis is defined as a uniform swelling of the whole digit that results from inflammation in the joints, tendons, and soft tissues and presents as a “sausage digit”1. It is a common feature of psoriatic arthritis (PsA), occurring in 48% of the patients, and is one of the features of ClASsification for Psoriatic ARthritis (CASPAR) criteria2,3. Dactylitis is associated with impaired function and is a marker of disease severity2. Dactylitis may occur acutely, as a tender swollen digit, or chronically, as a swollen digit that is no longer tender4. Randomized clinical trials in PsA have shown remarkable response to treatment with biological agents, with improvement in the active joint count, psoriasis, quality of life, and function5. However, the data on significant improvement of dactylitis in randomized clinical trials have been sparse6,7,8. There are data from uncontrolled trials suggesting improvement in dactylitis using other anti-tumor necrosis factor-α (anti-TNF) agents9,10,11. Whether anti-TNF agents lead to better response in dactylitis than conventional disease-modifying antirheumatic drugs (DMARD) in clinical practice has not been assessed.

The objectives of our study were to determine the prevalence of acute dactylitis in patients with PsA and to compare the response of new acute dactylitis to treatment with traditional DMARD and anti-TNF agents in a longitudinal PsA cohort.

MATERIALS AND METHODS

Patients and assessments

Patients with PsA are followed at the University of Toronto PsA clinic at the Toronto Western Hospital at 6 to 12–month intervals according to a common protocol12. At each visit, patients are assessed clinically with a complete history and examination that includes actively inflamed and damaged joint counts, assessment of dactylitis (based on the presence of a uniform swelling of a whole digit), and enthesitis and spinal measures, as well as a detailed medication history. Patients who were followed at the PsA clinic from January 2000 to January 2010 were included in our study, because biologic agents became available in 2000. The Leeds Dactylitis Index has been used in the PsA clinic since 2008. However, in our study only the presence of acute dactylitis and the number of digits with dactylitis were considered.

Outcome

Acute dactylitis was defined as the presence of painful swelling of an entire digit. Response was defined as either complete resolution of dactylitis or > 50% improvement in the number of dactylitic digits.

Statistical analysis

The prevalence of dactylitis in this cohort was determined. Descriptive statistics of the demographic and disease characteristics of the patients in the study were obtained. The response of “acute dactylitis events” to therapy with DMARD was compared to that during treatment with anti-TNF agents at 6 and 12 months using chi-square analyses. A multivariate analysis with generalized estimating equations using a negative binomial model to account for repeated measures was conducted to compare response to treatment and determine predictors for response. The variables entered into the model were age, sex, duration of disease, treatment, and intraarticular steroid use where treatment was categorized as no treatment, biologics (± DMARD), and DMARD.

RESULTS

Of the 752 patients seen in the PsA clinic during this period, 294 had acute dactylitis identified in at least 1 visit, giving a prevalence of 39%. Two hundred fifty-two patients with acute dactylitis had complete data available for response at 6 and 12 months. These patients were included in the study on the predictors of response to treatment. Of the 252 patients, 34% were women, the mean age was 47 years, PsA duration 11 years, mean actively inflamed joint count 13.3, mean damage joints 9.7, and Psoriasis Area and Severity Index score was 5.6 (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Demographic and disease characteristics.

At 6 months, 77.3% of the patients responded to therapy when taking biologics in comparison to 51.5% taking DMARD. Similarly, at 12 months, 87.2% of the patients responded to therapy when taking biologics in comparison to 69.9% taking DMARD.

Multivariate analysis showed that only treatment type (anti-TNF agents vs DMARD) was a significant predictor of response of dactylitis at 12 months, with a relative risk of 0.528 (95% CI 0.283–0.985, p = 0.045). There was a trend showing response at 6 months (p = 0.061; Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Multivariate analysis.

DISCUSSION

The prevalence of dactylitis in patients enrolled in the University of Toronto cohort during this decade was 39%. This is similar to the prevalence of dactylitis reported in other series2,13. Because acute dactylitis is most likely to respond to therapy, we studied the effect of treatment in those with acute dactylitis, and included patients who had data available for both 6 and 12 months of treatment. This is the first study, to our knowledge, to compare response to therapy with conventional and biologic agents in PsA patients with dactylitis. Although this was not a randomized controlled trial, it did allow us to perform a comparison, because the information was collected prospectively. There were fewer events of new acute dactylitis in patients treated with anti-TNF agents in comparison to those treated with DMARD. Significantly more dactylitis events improved on treatment with anti-TNF agents compared to treatment with DMARD. While the specificity of the improvement in dactylitis might have been clearer had we included only patients who had isolated dactylitis, this would be an unusual situation because the number of patients who present only with dactylitis is low and would preclude drawing any conclusions. It should be noted, however, that the aim of our study was to evaluate the potential for improvement with traditional DMARD and anti-TNF agents on this particular aspect of the disease, in the context of the usual presentation of PsA.

The use of the Leeds Dactylitis Index might have provided a better measure of response1, but it was not available for patients seen prior to 2008 and therefore could not be used in our study.

It should be noted that conventional DMARD did help a large proportion of patients with acute dactylitis. This is in contrast to the reports of randomized clinical trials using conventional DMARD in the treatment of dactylitis. Helliwell summarized these reports6 and concluded that sulfasalazine provided a very low effect size of 0.2 and leflunomide provided a better effect size of 0.33, but the information was not provided in that report, and cyclosporine could not be assessed. Based on that literature review, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommended that for patients with dactylitis, anti-TNF agents should be used when the condition is considered moderate to severe14.

A randomized controlled trial comparing traditional DMARD and biologic agents for the treatment of dactylitis seems warranted to provide evidence for the treatment recommendations for dactylitis.

Footnotes

  • Supported by a grant from the Krembil Foundation. Dr. Ziouzina was supported by a grant from Janssen Canada. Dr. Chandran was supported by the Canadian Institutes for Health Research New Emerging Grant.

  • Accepted for publication April 19, 2013.

REFERENCES

  1. 1.↵
    1. Coates LC,
    2. Helliwell PS
    . Disease measurement — enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 2010;24:659–70.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Brockbank J,
    2. Stein M,
    3. Schentag CT,
    4. Gladman DD
    . Dactylitis in psoriatic arthritis (PsA): A marker for disease severity? Ann Rheum Dis 2005;62:188–90.
    OpenUrl
  3. 3.↵
    1. Taylor WJ,
    2. Gladman DD,
    3. Helliwell PS,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H
    . Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Healy PJ,
    2. Helliwell PS
    . Dactylitis: pathogenesis and clinical considerations. Curr Rheumatol Rep 2006;8:338–41.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Saad AA,
    2. Symmons DP,
    3. Noyce PR,
    4. Ashcroft DM
    . Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883–90.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Helliwell PS
    . Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439–41.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Antoni CE,
    2. Kavanaugh A,
    3. Kirkham B,
    4. Tutuncu Z,
    5. Burmester GR,
    6. Schneider U,
    7. et al.
    Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227–36.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Kavanaugh A,
    2. Mease P
    . Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).J Rheumatol Suppl. 2012 Jul;89:90–3.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gladman DD,
    2. Sampalis JS,
    3. Illouz O,
    4. Guerette B
    . Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: Effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898–906.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Salvarani C,
    2. Pipitone N,
    3. Catanoso M,
    4. Chiarolanza I,
    5. Boiardi L,
    6. Caruso A,
    7. et al.
    Adalimumab in psoriatic arthritis. J Rheumatol Suppl. 2012 Jul;89:77–81.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Gladman DD,
    2. Bombardier C,
    3. Thorne C,
    4. Haraoui B,
    5. Khraishi M,
    6. Rahman P,
    7. et al.
    Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: The REPArE (Rating Evaluations in Psoriatic Arthritis with Enbrel) trial. J Rheumatol 2011;38:1355–62.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Gladman DD,
    2. Chandran V
    . Observational cohort studies: Lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology 2011;50:25–31.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Carneiro JN,
    2. Paula AP,
    3. Martins GA
    . Psoriatic arthritis in patients with psoriasis: Evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasilia. An Bras Dermatol 2012;87:539–44.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ritchlin CT,
    2. Kavanaugh A,
    3. Gladman DD,
    4. Mease PJ,
    5. Boehncke WH,
    6. de Vlam K,
    7. et al.
    Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 8
1 Aug 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era
Dafna D. Gladman, Olga Ziouzina, Arane Thavaneswaran, Vinod Chandran
The Journal of Rheumatology Aug 2013, 40 (8) 1357-1359; DOI: 10.3899/jrheum.130163

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era
Dafna D. Gladman, Olga Ziouzina, Arane Thavaneswaran, Vinod Chandran
The Journal of Rheumatology Aug 2013, 40 (8) 1357-1359; DOI: 10.3899/jrheum.130163
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

SPONDYLOARTHRITIS
DISEASE-MODIFYING ANTIRHEUMATIC DRUG
INFLAMMATION
BIOLOGICS
DACTYLITIS

Related Articles

Cited By...

More in this TOC Section

  • Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program
  • Do Patterns of Early Disease Severity Predict Grade 12 Academic Achievement in Youths With Childhood-Onset Chronic Rheumatic Diseases?
  • High Prevalence of Foot Insufficiency Fractures in Patients With Inflammatory Rheumatic Musculoskeletal Diseases
Show more Articles

Similar Articles

Keywords

  • spondyloarthritis
  • disease-modifying antirheumatic drug
  • inflammation
  • biologics
  • dactylitis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire